Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Blocks Indian Trastuzumab; Says No Room For ''Uncertainty''

This article was originally published in Scrip

Executive Summary

Roche has moved to block Reliance Life Sciences Pvt Ltd's biosimilar version of its anticancer Herceptin (trastuzumab) in India citing "genuine" concern over the comparable safety and efficacy of the Indian firm's product.

You may also be interested in...



Court: No Herceptin Biosimilar Tag For Indian Trastuzumabs

An Indian court appears to have delivered a frontal blow to defendants Biocon and Mylan in a hotly contested case concerning their biosimilar versions of Roche's Herceptin (trastuzumab).

Court: No Herceptin Biosimilar Tag For Indian Trastuzumabs

An Indian court appears to have delivered a frontal blow to defendants Biocon and Mylan in a hotly contested case concerning their biosimilar versions of Roche's Herceptin (trastuzumab).

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.

Topics

Related Companies

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel